✦ LIBER ✦

Corrections to AASLD guidelines on chronic hepatitis B

✍ Scribed by Anna S. F. Lok; Brian J. McMahon

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 68 KB
Volume: 45
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21738

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

AASLD practice guidelines on chronic hep

AASLD practice guidelines on chronic hepatitis B and HBV infection in Italy

✍ Tommaso Stroffolini; Giovanni Battista Gaeta; Alfonso Mele 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

We thank Fazili et al. for their interest in our article. The development of antibodies to hepatitis B e antigen (anti-HBe) and hepatitis B surface antigen (anti-HBs) were lower in the lamivudine-treated group relative to placebo, although these did not reach statistical significance. We concur with

Corrections to the AASLD Practice Guidel

Corrections to the AASLD Practice Guideline

✍ David A. Hendricks 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

We read with great interest and enthusiasm the updated American Association for the Study of Liver Diseases practice guidelines, "Diagnosis, Management, and Treatment of Hepatitis C" by Strader et al., who comprehensively reviewed the current status and pointed out areas requiring more studies. 1 Un

Correction: “Clinical utility of hepatit

Correction: “Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review”

📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 1 views

In the June 2011 issue of HEPATOLOGY, in the article entitled ''Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review'' (volume 53, pages 2121-2129) the data in Tables 2 and3 are to be corrected as listed below: On page 2124, under the heading '

Prediction of sustained response to pegi

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Effect of corticosteroid therapy on leve

Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis

✍ Maria H. Sjogren; Jay H. Hoofnagle; Jeanne G. Waggoner 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 405 KB 👁 2 views

## Serum levels of antibody to hepatitis B core antigen and IgM antibody to hepatitis B core antigen were tested in 15 patients who participated in a randomized, placebo-controlled trial of a 28-day course of prednisolone therapy. During treatment, serum levels of antibody to hepatitis B core anti

Natural course and response to interfero

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

✍ Maurizia Rossana Brunetto; Filippo Oliveri; Giuseppe Rocca; Domenico Criscuolo; 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 568 KB

The course of chronic hepatitis B was studied in 30 patients who had antibody to hepatitis e antigen and hepatitis B virus DNA in the serum and hepatitis B core antigen in the liver. Over a 2-year period, no patient experienced a sustained spontaneous remission of disease, and follow-up liver histol